Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
$203.56
-$1.02(-1.54%)
At close: 4:00 PM EST
$203.56
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$60.40 - $205.11
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.10M
Market Cap
$43.41B
Enterprise Value$29.56B
Total Cash (Recent Filing)$1.68B
Total Debt (Recent Filing)$745.08M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Feb 19, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding213,273,470
10 Day Avg. Volume2,014,315
30 Day Avg. Volume2,103,998
Financial Highlights & Ratios
PEG Ratio-2.88
Price to Book (P/B)39.69
Price to Sales (P/S)31.14
P/FCF Ratio-16.05
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue66.13
Enterprise Value/Gross Profit94.51
Enterprise Value/Ebitda-27.22
Forecast
1Y Price Target
$200.31Price Target Upside-1.60% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-6.12
Revenue Forecast (FY)$503.90M
Bulls Say, Bears Say
Bulls Say
Financial OutlookCash reserves of $1.7B provide a significant runway, potentially reaching break-even.
Product Approval And LaunchBrinsupri, INSM's 1st-gen neutrophil elastase inhibitor, received formal EC approval for NCFBE 'with 2+ exacerbations' in the prior year.
Sales PerformanceBrinsupri revenue of $28.1M strongly beat analyst and market expectations, supporting a strong early launch.
Bears Say
Management GuidanceMgmt sounded cautionary on 4Q, but KOL survey more bullish.
Market ExpectationsThere is caution against over-interpreting early Brinsupri sales figures, with a clearer understanding expected after the first full quarter of revenue.
Regulatory ChallengesThe EU label indication includes the exacerbation requirement, which is more restrictive than the US label which does not include exacerbation language.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $60.40 and its highest was $205.11 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $43.41B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Feb 19, 2026 which is in 90 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Oct 30, 2025. The company reported -$1.75 earnings per share for the quarter, missing the consensus estimate of -$1.329 by -$0.421.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Overvalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.26.
How many shares outstanding does Insmed have?
Insmed has 213,273,470 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.75 in its last earnings report, missing expectations of -$1.329. Following the earnings report the stock price went up 16.334%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$200.31 (-1.60% Downside)
$200.31 (-1.60% Downside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.12%
12-Months-Change
Fundamentals
Return on Equity
-165.69%
Trailing 12-Months
Asset Growth
14.99%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious and rare diseases. The company primarily operates in the biotechnology sector, with a strong emphasis on developing treatments for conditions such as cystic fibrosis and pulmonary diseases. Insmed's core products include its lead product candidate, which targets rare respiratory conditions, enhancing the quality of life for affected patients.
INSM Company Deck
INSM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant achievements, particularly the strong launch of BRINSUPRI and robust performance of ARIKAYCE. However, the company expressed caution about the early dynamics of the BRINSUPRI launch and uncertainties in market access, indicating a balanced outlook.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$200.31
▼(-1.60% Downside)
Technical Analysis
Ownership Overview
0.91% Insiders
31.43% Mutual Funds
11.90% Other Institutional Investors
42.10% Public Companies and Individual Investors